BTAI director acquires 1,694 shares; now holds 20,317

BioXcel Therapeutics (BTAI) director David J. Mack reported the vesting and settlement of 1,694 shares of Common Stock on 10/31/2025 from previously granted RSUs.

Rhea-AI Filing Summary

BioXcel Therapeutics (BTAI) director David J. Mack reported the vesting and settlement of 1,694 shares of Common Stock on 10/31/2025 from previously granted RSUs. Following the transaction, he beneficially owned 20,317 shares, held directly.

The RSUs were part of a grant made on November 21, 2024, totaling 20,317 RSUs, scheduled to vest in twelve equal monthly installments beginning November 30, 2024, subject to continued service as a Director.

Insider Trade Summary

1,694 shares exercised/converted

Exercise 2 txns

Insider MACK DAVID J.

Role Director

Type	Security	Shares	Price	Value
Exercise	Restricted Stock Units	1,694	$0.00	$0.00
Exercise	Common Stock	1,694	$0.00	$0.00

Holdings After Transaction: Restricted Stock Units — 0 contracts (Direct); Common Stock — 20,317 shares (Direct)

Footnotes (2)

1. F1. Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock.
2. F2. On November 21, 2024, the Reporting Person was granted 20,317 RSUs, vesting in twelve equal installments on the last date of each month beginning on November 30, 2024, subject to his continued service as a Director through the vesting period.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did BTAI director David J. Mack report on Form 4?

He reported the vesting and settlement of 1,694 shares of Common Stock on 10/31/2025 from RSUs.

How many BTAI shares does David J. Mack own after the transaction?

He beneficially owned 20,317 Common Stock shares, held directly, following the reported transaction.

What is the source of the 1,694 BTAI shares reported?

They were delivered upon vesting of Restricted Stock Units (RSUs) previously granted.

When were the RSUs originally granted to the BTAI director?

The RSUs were granted on November 21, 2024, totaling 20,317 RSUs.

What is the vesting schedule for the granted BTAI RSUs?

They vest in twelve equal installments on the last day of each month beginning November 30, 2024, subject to continued service.

What was the transaction code for the RSU conversion?

The transaction code was M, indicating a conversion of derivative securities (RSUs) into Common Stock.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 11/03/2025 - 08:00 PM EST Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

MACK DAVID J.

(Last) (First) (Middle)

C/O BIOXCEL THERAPEUTICS, INC.

555 LONG WHARF DRIVE, 12TH FLOOR

(Street)

NEW HAVEN CT 06511

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
BioXcel Therapeutics, Inc. [ BTAI ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
10/31/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	10/31/2025		M		1,694	A	(1)	20,317	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	(1)	10/31/2025		M			1,694	(2)	(2)	Common Stock	1,694	$0	0	D

Explanation of Responses:

1. Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock.

2. On November 21, 2024, the Reporting Person was granted 20,317 RSUs, vesting in twelve equal installments on the last date of each month beginning on November 30, 2024, subject to his continued service as a Director through the vesting period.

	/s/ Richard Steinhart, Attorney-in-Fact for David J. Mack	11/03/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.